A generic cardiovascular drug called mexiletine, initially developed to treat heart rhythm abnormalities, appears to hold some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs),
Antisense oligonucleotides – short segments of genetic material designed to target specific areas of a gene
The new approach could have implications for many genetic diseases.
ROSEVILLE, CA (January 25, 2012): The Myotonic Dystrophy Foundation (MDF) is pleased to announce its largest-ever round of Fund-A-Fellow postdoctoral fellowship research grant awards.
Sitemap | User Agreement
© Myotonic Dystrophy Foundation. All rights reserved.